Last reviewed · How we verify
A Study to Investigate HCV Response Rates in Real World Patients Traditionally Excluded From Clinical Trials: The HEARTLAND Study
This is a Phase IV, open label, single center study of OBV/PTV/r + DSV +/- RBV for 12 or 24 weeks for the treatment of chronic HCV-1 infection in a real world urban clinical setting.
Details
| Lead sponsor | American Research Corporation |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 100 |
| Start date | 2016-03 |
| Completion | 2017-09 |
Conditions
- Chronic Hepatitis C
Interventions
- paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin
Primary outcomes
- The primary analysis will be sustained virologic response 12 weeks after the last treatment dose (SVR12) for the all treated population. — 12 weeks after last treatment
Primary Analysis